Latest news
Loading news…
GlyProVac
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 HighHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Odense, Syddanmark, Denmark Founded 2018 1-10 employees For Profit
GlyProVac is pursuing the development of a glycoprotein based vaccine against Enterotoxigenic Escherichia coli (ETEC).
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
0
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 3
- IT spend
- $102K
Company Info
- Founded
- 2018
- Employees
- 1-10
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- HQ
- Odense, Syddanmark, Denmark
- Region
- European Union (EU), Nordic Countries, Scandinavia
Signals & Scores
- Heat score
- High
- Growth score
- Low
- Trend (7d)
- 0
- Trend (30d)
- 0
- Trend (90d)
- 0
Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to GlyProVac
Loading news…
FAQs about GlyProVac
People who checked this page also checked these
Browse the full Acquirezy directory.